Skip to main content
Fig. 6 | BMC Genomic Data

Fig. 6

From: Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

Fig. 6

A mRNA levels of FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP in breast cancer samples and adjacent normal breast tissues were analyzed using the GEPIA database. The method for differential analysis was one-way ANOVA. Statistical significance of differences in mRNA levels was set at p < 0.01 (*). B Analysis of gene expression of FABP, ADIPOQ, PPARG, CD36, PPARGC1A, and CREBBP in basal-like and TNBC cells with bc-GenExMiner using TCGA study data. The difference of gene expression in the different population groups was analyzed using Welch’s test. Statistical significance was set at P-value < 0.01. C Protein level of FABP4, ADIPOQ, PPARG, PPARGC1A, CD36, and CREBBP in normal and breast tumor tissues were analyzed using the Human Protein Atlas (HPA)

Back to article page

BMC Genomic Data

ISSN: 2730-6844

Contact us